Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis

OBJECTIVES: Retroperitoneal fibrosis (RPF) is a rare autoimmune disease with fibrous tissue growth and inflammation in retroperitoneum. Its current treatments involve long-term uptake of glucocorticoids (e.g., prednisone) for controlling inflammation; however, side effects are common. We strived for...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Hui, Liu, Shibo, Mai, Yuanbang, Wang, Yuying, Zhang, Xuewu, Zheng, Shufen, Luo, Chenghua, Pan, Cuiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Autoinflammatory Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176363/
https://www.ncbi.nlm.nih.gov/pubmed/36720581
http://dx.doi.org/10.1136/ard-2022-223736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176363/
https://www.ncbi.nlm.nih.gov/pubmed/36720581
http://dx.doi.org/10.1136/ard-2022-223736

Ejemplares similares